Role of intravenous lipid emulsions in the management of calcium channel blocker and β-blocker overdose: 3 years experience of a university hospital

2015 ◽  
Vol 127 (2) ◽  
pp. 119-124 ◽  
Author(s):  
Ahmet Sebe ◽  
Nezihat Rana Dişel ◽  
Ayça Açıkalın Akpınar ◽  
Emre Karakoç
2020 ◽  
Vol 16 ◽  
Author(s):  
Seiji Umemoto ◽  
Toshio Ogihara ◽  
Masunori Matsuzaki ◽  
Hiromi Rakugi ◽  
Kazuyuki Shimada ◽  
...  

Background: In the trial known as COPE (Combination Therapy of Hypertension to Prevent Cardiovascular Events) three benidipine (a calcium channel blocker; CCB) regimens were compared. Hypertensive Japanese outpatients aged 40–85 years (n=3,293) who did not achieve the target blood pressure of <140/90 mmHg with benidipine 4 mg/day were treated with the diuretic thiazide (n=1,094) or a β-blocker (n=1,089) or an additional angiotensin receptor blocker (ARB; n=1,110). A significantly higher incidence of hard cardiovascular composite endpoints and of fatal or non-fatal strokes was observed in the benidipine-β-blocker group compared to the benidipine-thiazide group. Objective and Methods: We further evaluated the treatment effects of the three benidipine-based regimens on vascular and renal events in a sub-analysis of the COPE patients. Results: A total of 10 vascular events (0.8 per 1,000 person-years) including one aortic dissection (0.1 per 1,000 person-years) and nine cases of peripheral artery disease (0.8 per 1,000 person-years) were documented, as was a total of seven renal events (0.6 per 1,000 person-years). No significant differences in vascular and renal events were revealed among the three treatment groups: vascular events p=0.92 renal events p=0.16 log-rank test. Conclusions: Blood pressure-lowering therapy with benidipine combined with an ARB, β-blocker, or thiazide was similarly effective in the prevention of vascular and renal events in hypertensive outpatients, although there is no enough these events to compare the difference in the three treatment groups.


2018 ◽  
Vol 36 (4) ◽  
pp. 736.e5-736.e6 ◽  
Author(s):  
Karan Seegobin ◽  
Satish Maharaj ◽  
Ansuya Deosaran ◽  
Pramod Reddy

2020 ◽  
Vol 13 (01) ◽  
pp. 1-11
Author(s):  
Noverio Tarukallo ◽  
Haerani Rasyid

Salah satu faktor yang memiliki risiko yang terkait dengan kejadian disfungsi seksual pada pria adalah obat anti-hipertensi. Obat anti-hipertensi yang memiliki efek menyebabkan disfungsi seksual pada pria termasuk; diuretik, Clonidine, dan β-blocker (kecuali nebivolol), tetapi ada beberapa obat anti-hipertensi yang memiliki efek netral, bahkan memiliki efek positif yang dalam hal ini dapat meningkatkan fungsi seksual pada pria. Obat anti-hipertensi yang memiliki efek netral pada fungsi seksual pria meliputi; Calcium Channel Blocker dan ACE-Inhibitor dan yang memiliki efek meningkatkan fungsi seksual pada pria termasuk; ARB dan β-blocker yaitu nebivolol. Penggunaan obat anti-hipertensi dapat mempengaruhi fungsi seksual pada pria melalui mekanisme yang berbeda. Obat anti-hipertensi seperti diuretik, β-blocker, dan clonidine dapat menyebabkan disfungsi seksual pada pria melalui mekanisme perubahan dalam aliran simpatis, efek pada kontraksi otot polos fisik, dan melalui pengaruh pada kadar hormon androgen. Angiotensin Receptor Blocker dan Nebivolol dapat meningkatkan fungsi seksual melalui mekanisme penghambatan pada Angiotensin II dan meningkatkan bioavailabilitas Nitric Oxide.


Sign in / Sign up

Export Citation Format

Share Document